FCGR2B and melanoma: Similarly, the antibody targeting macrophage receptor with the collagenous structure (MARCO), by crosslinking the inhibitory FcgRIIB on TAMs, synergistically increases anti-CTLA4 immunotherapy in melanoma and colon cancer mouse models.